IL237745A0 - Use of lequinimod to reduce damage to the thalamus in multiple sclerosis - Google Patents
Use of lequinimod to reduce damage to the thalamus in multiple sclerosisInfo
- Publication number
- IL237745A0 IL237745A0 IL237745A IL23774515A IL237745A0 IL 237745 A0 IL237745 A0 IL 237745A0 IL 237745 A IL237745 A IL 237745A IL 23774515 A IL23774515 A IL 23774515A IL 237745 A0 IL237745 A0 IL 237745A0
- Authority
- IL
- Israel
- Prior art keywords
- laquinimod
- multiple sclerosis
- thalamic damage
- reducing thalamic
- reducing
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
- 229960004577 laquinimod Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
- 230000000542 thalamic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064061 WO2014058979A2 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237745A0 true IL237745A0 (en) | 2015-05-31 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237745A IL237745A0 (en) | 2012-10-12 | 2015-03-15 | Use of lequinimod to reduce damage to the thalamus in multiple sclerosis |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (https=) |
| EP (1) | EP2961406A4 (https=) |
| JP (1) | JP2015533163A (https=) |
| KR (1) | KR20150080509A (https=) |
| CN (1) | CN105263325A (https=) |
| AR (1) | AR092993A1 (https=) |
| AU (2) | AU2013329348A1 (https=) |
| BR (1) | BR112015007782A2 (https=) |
| CA (1) | CA2884272A1 (https=) |
| CL (2) | CL2015000732A1 (https=) |
| EA (1) | EA201590726A1 (https=) |
| HK (1) | HK1218865A1 (https=) |
| IL (1) | IL237745A0 (https=) |
| MX (1) | MX2015004564A (https=) |
| PE (1) | PE20151435A1 (https=) |
| SG (1) | SG11201501874TA (https=) |
| TW (1) | TW201420101A (https=) |
| WO (1) | WO2014058979A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| BR112015019564A2 (pt) * | 2013-02-15 | 2017-07-18 | Teva Pharma | tratamento de esclerose múltipla com laquinimod |
| CA2933380A1 (en) * | 2013-12-20 | 2015-06-25 | Esther Lukasiewicz Hagai | Use of laquinimod to delay huntington's disease progression |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| CN110461318A (zh) * | 2016-09-13 | 2019-11-15 | 因特克林治疗股份有限公司 | 用chs-131治疗多发性硬化 |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1850840A2 (en) * | 2005-01-13 | 2007-11-07 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| AU2007276405A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Sulphonylaminocarbonyl derivatives of bile acid amides for use as immunomodulators |
| AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| EP2523668A1 (en) * | 2010-01-13 | 2012-11-21 | Ramot at Tel-Aviv University Ltd | Treatment of multiple sclerosis |
| AU2011338647A1 (en) * | 2010-12-07 | 2013-07-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
| CA2830027C (en) * | 2011-03-31 | 2016-04-26 | Pfizer Inc. | Novel bicyclic pyridinones |
| CA2851525A1 (en) * | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201590726A1 (ru) | 2015-10-30 |
| WO2014058979A2 (en) | 2014-04-17 |
| CL2016002873A1 (es) | 2017-04-17 |
| CA2884272A1 (en) | 2014-04-17 |
| CN105263325A8 (zh) | 2017-07-14 |
| WO2014058979A3 (en) | 2015-08-20 |
| BR112015007782A2 (pt) | 2017-07-04 |
| US20160296511A1 (en) | 2016-10-13 |
| AU2017203896A1 (en) | 2017-06-29 |
| HK1218865A1 (zh) | 2017-03-17 |
| CN105263325A (zh) | 2016-01-20 |
| EP2961406A2 (en) | 2016-01-06 |
| MX2015004564A (es) | 2015-07-21 |
| AR092993A1 (es) | 2015-05-13 |
| CL2015000732A1 (es) | 2015-08-07 |
| AU2013329348A1 (en) | 2015-05-28 |
| PE20151435A1 (es) | 2015-10-15 |
| US20140107154A1 (en) | 2014-04-17 |
| JP2015533163A (ja) | 2015-11-19 |
| EP2961406A4 (en) | 2017-01-04 |
| SG11201501874TA (en) | 2015-05-28 |
| WO2014058979A8 (en) | 2015-04-16 |
| TW201420101A (zh) | 2014-06-01 |
| KR20150080509A (ko) | 2015-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237745A0 (en) | Use of lequinimod to reduce damage to the thalamus in multiple sclerosis | |
| ZA201504200B (en) | Beta-lactamase inhibitors | |
| IL230511A0 (en) | 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors | |
| EP2764428A4 (en) | MULTI-DIMENSIONAL INTERFACE | |
| EP2844523A4 (en) | HALTEDOCK | |
| GB201212096D0 (en) | Improved cleaning formulation and method | |
| ZA201402148B (en) | Coolant formulations | |
| GB201208548D0 (en) | Compound and method | |
| AP2015008406A0 (en) | Benzamides | |
| IL229262A0 (en) | Superstructure and methods for its production | |
| PL2748267T3 (pl) | Sposób ochrony powierzchni | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| PL2667710T3 (pl) | Kompozycja owadobójcza i związane z nią sposoby | |
| PL2805796T3 (pl) | Sposób szlifowania | |
| PL2527081T3 (pl) | Centrum obróbkowe i sposób obróbki | |
| IL232938A0 (en) | A pharmaceutical preparation used to reduce damage caused by free radicals | |
| EP2847733A4 (en) | PROCEDURE AND ARRANGEMENTS FOR THE EXCHANGE OF TRADEMARKED PRODUCTS | |
| IL236154A0 (en) | compound and method | |
| ZA201406489B (en) | Workpiece positioning structure and workpiece positioning method | |
| SG10201703786YA (en) | Nox removal method | |
| PT2734544T (pt) | Métodos e composições para inibir a patologia associada a poliomavírus | |
| GB201117816D0 (en) | CE No Damage Tools | |
| GB201215501D0 (en) | Social multi-media tool | |
| GB201109246D0 (en) | New removal tool and barrier design | |
| GB201213160D0 (en) | Method and compound |